SCRI Development Innovations- Oncology-focused CRO

SCRI Development Innovations (SCRI Innovations) is a global, full-service, oncology-focused contract research organization (CRO) specializing in clinical development services for first-in-human through proof-of-concept trials. As the CRO division of Sarah Cannon Research Institute, SCRI Innovations leverages strong scientific leadership and drug development expertise to design and implement optimal trials that effectively and efficiently lead to clinical decisions. SCRI Innovations is connected to a broad pool of cancer patients via its relationship with Sarah Cannon Research Institute’s Strategic Sites along with its network of 40 preferred sites that encompass approximately 200 referring community physicians. Our fast and flexible capabilities support a seamless partnership with sponsors to provide innovative solutions in an ever-changing drug development environment that ultimately lead to improved patient outcomes.

SCRI Innovations Key Differentiators/Offerings

  • Partnership that truly supports collaboration
  • Proven Processes that enable timely delivery of trials from concept to completion
  • Quality Delivery

SCRI Innovations Value

  • Full-service CRO capabilities with stand-alone functional expertise
  • Clinical Development strategy services
  • Early-phase oncology experts
  • Practicing MD study chair
  • Quality delivery with flexibility
  • Expansive patient outreach
  • SMO Relationship
  • Global capabilities
  • Sponsor endorsed

Contact Us